en · de · pt
reference-notes.peptides9000.com › News › Retatrutide Background And Design — Complete Guide

Retatrutide Background And Design — Complete Guide

By Editorial Desk · published 2026-04-27 · last reviewed 2026-05-19 · News

This is a working overview of 瑞他鲁肽, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.

Retatrutide Background and Design

Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.

The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.

瑞他鲁肽开发背景

瑞他鲁肽是一种在研合成肽,同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别,尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病,研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果;最终疗效、长期安全性和适用人群仍属开放问题。

开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示,参与者在体重和相关代谢指标上出现变化,但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置,以区分药物效应与行为干预。监管提交和标签范围尚未确定;长期维持效果与心血管结局仍是开放问题。

Retatrutide at a glance

PropertyValueNotes
Molecular classSynthetic peptideNot a small molecule
Receptor targetsGLP-1, GIP, glucagonTriple agonist activity
AppearanceWhite to off-white powderLyophilized solid
SolubilitySoluble in waterAlso in aqueous buffers
Storage−20 °C or belowProtect from light and moisture

分析表征与稳定性管理

多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质,质谱用于确认分子量,肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用,可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。

稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上,氧化常涉及甲硫氨酸与色氨酸,聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。

Related pages on this site

Peptide Identity and Receptor Targets

Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.

Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.

Notes from published material

It has also been discovered that GLD2 has medical uses. For example, such enzyme is overexpressed in patients who suffer from cancer; that's why it can be used as a prognostic factor for early appearance in breast cancer patients. Moreover, PAP activity is used to measure the effect of anticancer drugs as etoposide and cordycepin in two carcinoma cell lines: HeLa, which is the human epithelioid cervix carcinoma, and MCF-7 (human breast cancer). However, in spite its utilities it can also be involved in the expression of several common diseases such as: leukemia, liver cirrhosis, brain injuries, hepatitis and in some cases infertility in male patients.

Amylopectin has seen a rise of use in biomedical applications due to its physiological factors, ease of availability, and low cost. Specifically, amylopectin has very advantageous biochemical properties due to its prevalence as a natural polysaccharide. This causes a high sense of biocompatibility with cells and molecules within the body. Amylopectin is also able to biodegrade to a high degree due to its high sense of crosslinking with 1,6 glycosidic bonds. The bonds easily broken down by the body can reduce molecular weight, expose certain regions, and interact certain bonds with clinical factors. Various physical, chemical, and enzymatic methods of modification have also been researched for amylopectin. These, generally, allow for enhanced and controllable properties which can be selected for the field of research performed. Amylopectin's main role, clinically, is within its integration in starch. Function and structure of amylopectin is based on its integration with amylose and other bounded molecules. Separating these molecules and isolated amylopectin is quite difficult for researchers to perform.

16. Curr Opin Investig Drugs. 2004 Apr;5(4):456-62. PT-141 Palatin. Hedlund P(1). Author information: (1)Department of Clinical Pharmacology, University of Lund, F-blocket, Universitetssjukhuset, 22185 Lund, Sweden. petter.hedlund@klinfarm.lu.se Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.

Sources: en.wikipedia.org

Background from the literature

The angiotensin II receptors, (ATR1) and (ATR2), are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin–angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors share a sequence identity of ~30%, but have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. The AT1 subtype is found in the heart, blood vessels, kidney, adrenal cortex, lung and circumventricular organs of brain, basal ganglia, brainstem and mediates the vasoconstrictor effects. The angiotensin receptor is activated by the vasoconstricting peptide angiotensin II. The activated receptor in turn couples to Gq/11 and Gi/o and thus activates phospholipase C and increases the cytosolic Ca2+ concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C. Activated receptor also inhibits adenylate cyclase and activates various tyrosine kinases.

Microanalysis is the chemical identification and quantitative analysis of very small amounts of chemical substances (generally less than 10 mg or 1 ml) or very small surfaces of material (generally less than 1 cm2). One of the pioneers in the microanalysis of chemical elements was the Slovenian-Austrian Nobel Prize winner Fritz Pregl. The most known methods used in microanalysis include: Most of the spectroscopy methods: ultraviolet–visible spectroscopy, infrared spectroscopy, nuclear magnetic resonance, X-ray fluorescence, Energy-dispersive X-ray spectroscopy, Wavelength-dispersive X-ray spectroscopy, and mass spectrometry Most of the chromatography methods : high-performance liquid chromatography, Gel permeation chromatography; Some thermal analysis methods: differential scanning calorimetry, thermogravimetric analysis; Electrophoresis; Field flow fractionation; X-ray diffraction; Combustion analysis. Compared to normal analyses methods, microanalysis:

5β-Pregnane, also known as 17β-ethyletiocholane or as 10β,13β-dimethyl-17β-ethyl-5β-gonane, is a steroid and a parent compound of a variety of steroid derivatives. It is one of the epimers of pregnane, the other being 5α-pregnane. Derivatives of 5β-pregnane include the naturally occurring steroids 5β-dihydroprogesterone, pregnanolone, epipregnanolone, pregnanediol, and pregnanetriol, and the synthetic steroids hydroxydione, renanolone, ORG-20599, and SAGE-217. These derivatives include metabolites of progesterone and endogenous and synthetic neurosteroids. Etiocholane Gonane

Sources: en.wikipedia.org

Reference notes

Upregulation of receptors is the increase in receptor number or sensitivity of receptors. The receptors involved in functional antagonism are regulated in sensitivity, number and location. Therefore, changes in receptors are common. Using a long-term antagonist drug or continuous exposure to an antagonist may cause the upregulation and hypersensitivity of receptors, which means an increase in the number and sensitivity of receptors. The increase in the number of receptors is due to the increased expression of receptors after prolonged inhibition. The upregulation of receptors is important in the clinical aspect. One example of upregulation of receptors is the upregulation of β-receptors caused by β receptor antagonists (also called β-blocker). The prolonged use of β-blockers results in the blockade of β-receptors, causing cells (mainly myocardial cells) to increase their expression of β-receptor. After removing the blockage, more receptors available for stimulation, resulting in higher sensitivity of β-receptors called the hypersensitivity of β-receptors. Abrupt discontinuation of β-blocker may potentially aggravate coronary artery disease, tachycardia, or even sudden cardiac death. Therefore, to prevent the adverse effects, doses of β-blocker must be reduced gradually over 10–14 days.

The book has generally been received well by the scientific community. According to Doty, those critical of the book range from people who refuse to read it to those who have semantic issues with the pheromone concept and its applicability to mammals. Peter Brennan argues that Doty does not consider some of the more recent scientific research that conflicts with his views. He cites a 2010 study in mice that reports the discovery of a urinary protein that attracts female mice. Brennan concludes: "I suspect that the majority of researchers will continue to use the term [pheromone], despite all of its shortcomings. But after reading this book, I will certainly be more circumspect when referring to pheromones in future."

Chattopadhyay's contributions in membrane and receptor biology and biophysics have been recognized by several awards and prizes. These include The World Academy of Sciences (TWAS) Prize, Shanti Swarup Bhatnagar Award, Ranbaxy Research Award, Prof. G.N. Ramachandran Gold Medal, SERB Distinguished Fellowship, Prof. G.N. Ramachandran 60th Birthday Medal and J.C. Bose Fellowship. He is an elected Fellow of The World Academy of Sciences, Royal Society of Biology, Royal Society of Chemistry, and all the Indian Academies of Science. Fellow, The World Academy of Sciences (2017) Fellow, The Royal Society of Biology (2017) Fellow, The Royal Society of Chemistry (2013) Fellow, Indian National Science Academy (2005) Fellow, Indian Academy of Sciences (1999) Fellow, The National Academy of Sciences, India (1998) Fellow, West Bengal Academy of Science & Technology (2010) Fellow, Andhra Pradesh Akademi of Sciences (2003) Fellow, Telangana Academy of Sciences (2015) Google Scholar

Sources: en.wikipedia.org

Frequently asked questions

What is retatrutide?

Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.

How does it differ from single-receptor agonists?

Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.

What is its current development status?

It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.

瑞他鲁肽是否已经上市?

尚未。它仍处于临床研究阶段,任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。

Network